Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study
Bunick C, Magnolo N, Moore A, Xinghua G, Lynde C, Ibrahim N, Grada A, Levy G, Calimlim B, Wu X, Armendariz Y, Eyerich K. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal Of Cutaneous Medicine 2024, 8: s451. DOI: 10.25251/skin.8.supp.451.Peer-Reviewed Original ResearchAtopic dermatitisSafety resultsInadequate responseEczema Area and Severity IndexWeeks post-switchEczematous skin lesionsOral Janus kinaseEffective treatment strategiesClinically meaningful improvementsClinically meaningful outcomesJanus kinaseChronic skin diseaseOptimal treatment targetsClinical responseMonotherapy studiesSkin clearanceSafety profileDupilumabTreatment strategiesInterleukin-13Interleukin-4UpadacitinibSafety signalsSwitch groupInterleukin-13 signaling696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.Peer-Reviewed Original ResearchSkin symptom severityPatient-reported outcomesAtopic dermatitisSkin painClinically meaningful improvementsUpadacitinib monotherapyPatients treated with upadacitinibPatients randomized to placeboSkin symptomsMeaningful improvementsQuality of lifeTreating moderate-to-severe ADModerate-to-severe ADPhase 3 studyDoses of upadacitinibMinimal clinically important differenceSustained improvementJanus kinase inhibitorsClinically important differenceEvaluate long-term benefitsReduced quality of lifeEczema AreaDLQI 0/1Symptom severityKinase inhibitors